LRP1 and atherosclerosis: Other recent work has developed antibodies against CR8/CR9 domain in the cluster II of LRP1, which are crucial for the interaction of this receptor with atherogenic lipoproteins, to prevent foam cell formation and atherosclerosis development [27,28].